JP2024525624A5 - - Google Patents
Info
- Publication number
- JP2024525624A5 JP2024525624A5 JP2024500541A JP2024500541A JP2024525624A5 JP 2024525624 A5 JP2024525624 A5 JP 2024525624A5 JP 2024500541 A JP2024500541 A JP 2024500541A JP 2024500541 A JP2024500541 A JP 2024500541A JP 2024525624 A5 JP2024525624 A5 JP 2024525624A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- drug conjugate
- conjugate according
- heavy chain
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110757803.1 | 2021-07-05 | ||
| CN202110757803 | 2021-07-05 | ||
| PCT/CN2022/103592 WO2023280092A1 (zh) | 2021-07-05 | 2022-07-04 | 抗体药物偶联物及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525624A JP2024525624A (ja) | 2024-07-12 |
| JP2024525624A5 true JP2024525624A5 (enExample) | 2025-06-23 |
Family
ID=84801059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500541A Pending JP2024525624A (ja) | 2021-07-05 | 2022-07-04 | 抗体薬物コンジュゲート及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240307551A1 (enExample) |
| EP (1) | EP4386006A4 (enExample) |
| JP (1) | JP2024525624A (enExample) |
| CN (1) | CN117616052A (enExample) |
| WO (1) | WO2023280092A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024263367A1 (en) * | 2023-04-27 | 2025-11-13 | CSPC Megalith Biopharmaceutical Co., Ltd. | Antibody-drug conjugate |
| CN116751319B (zh) * | 2023-07-19 | 2024-11-05 | 首都医科大学 | 一种壳聚糖六肽衍生物及其制备方法和应用 |
| CN120019819A (zh) * | 2023-11-17 | 2025-05-20 | 成都康弘生物科技有限公司 | 双毒素抗体药物偶联物及其用途 |
| WO2025113646A1 (zh) * | 2023-11-30 | 2025-06-05 | 江苏康宁杰瑞生物制药有限公司 | 包含pd-l1结合分子与双特异性抗体-药物偶联物的组合物及其用途 |
| WO2025242061A1 (zh) * | 2024-05-21 | 2025-11-27 | 正大天晴药业集团股份有限公司 | 抗her2抗体药物偶联物治疗胆道癌的用途 |
| WO2025247261A1 (zh) * | 2024-05-30 | 2025-12-04 | 爱尔利希生物科技有限公司 | 抗egfr抗体药物偶联物及其用途 |
| WO2025252039A1 (zh) * | 2024-06-03 | 2025-12-11 | 正大天晴药业集团股份有限公司 | 抗her2抗体药物偶联物治疗非小细胞肺癌的用途 |
| WO2026046156A1 (zh) * | 2024-08-27 | 2026-03-05 | 江苏康宁杰瑞生物制药有限公司 | 连接子—毒素分子化合物的制备方法及其中间体 |
| CN121109359A (zh) * | 2024-11-20 | 2025-12-12 | 华中科技大学同济医学院附属协和医院 | 一种靶向降解蛋白及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1771482T3 (da) | 2004-07-22 | 2014-10-20 | Genentech Inc | HER2-antistofsammensætning |
| CN102558355B (zh) | 2011-12-31 | 2015-02-25 | 苏州康宁杰瑞生物科技有限公司 | 基于电荷网络的异二聚体fc改造方法及异二聚体蛋白的制备方法 |
| CN102851338A (zh) | 2012-07-25 | 2013-01-02 | 苏州康宁杰瑞生物科技有限公司 | 利用电荷排斥作用制备同二聚体蛋白混合物的方法 |
| AU2014357292B2 (en) * | 2013-11-27 | 2020-06-25 | Zymeworks Bc Inc. | Bispecific antigen-binding constructs targeting HER2 |
| EP3083696B1 (en) * | 2013-12-20 | 2018-02-14 | F.Hoffmann-La Roche Ag | Bispecific her2 antibodies and methods of use |
| SG11201608192SA (en) * | 2014-04-11 | 2016-10-28 | Medimmune Llc | Bispecific her2 antibodies |
| CN110655582B (zh) * | 2015-01-08 | 2022-12-16 | 江苏康宁杰瑞生物制药有限公司 | 具有共同轻链的双特异性抗体或抗体混合物 |
| CN107446045A (zh) * | 2016-07-22 | 2017-12-08 | 北京天广实生物技术股份有限公司 | 一种抗her2的抗体、其药物组合物及用途 |
| CN113631580B (zh) * | 2019-02-03 | 2024-07-02 | 上海宝济药业股份有限公司 | 抗her2的双特异性抗体及其应用 |
| WO2021110107A1 (en) * | 2019-12-04 | 2021-06-10 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | COMBINATION OF BISPECIFIC FUSION PROTEIN AND ANTI-Her2 ANTIBODY FOR TUMOR TREATMENT |
| KR20220148200A (ko) * | 2020-02-28 | 2022-11-04 | 리제너론 파마슈티칼스 인코포레이티드 | Her2에 결합하는 이중특이적 항원 결합 분자 및 이의 사용 방법 |
| EP4117729A4 (en) * | 2020-04-15 | 2023-11-15 | Shenzhen Enduring Biotech, Ltd. | ANTIBODY DRUG CONJUGATE |
-
2022
- 2022-07-04 US US18/575,293 patent/US20240307551A1/en active Pending
- 2022-07-04 EP EP22836843.7A patent/EP4386006A4/en active Pending
- 2022-07-04 WO PCT/CN2022/103592 patent/WO2023280092A1/zh not_active Ceased
- 2022-07-04 CN CN202280047851.4A patent/CN117616052A/zh active Pending
- 2022-07-04 JP JP2024500541A patent/JP2024525624A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024525624A5 (enExample) | ||
| RU2624141C2 (ru) | Конъюгаты "антитело-лекарственное средство" | |
| AU2009212436B2 (en) | Camptothecin-binding moiety conjugates | |
| Stephan et al. | Challenges in developing bioanalytical assays for characterization of antibody–drug conjugates | |
| US20240307551A1 (en) | Antibody-drug conjugate and application thereof | |
| JP2016512832A5 (enExample) | ||
| JP2016518332A5 (enExample) | ||
| EP4378958A3 (en) | High-affinity anti-mertk antibodies and uses thereof | |
| JP2018501781A5 (enExample) | ||
| JP2016526042A (ja) | 抗体薬物コンジュゲート | |
| KR20250137203A (ko) | 항체 약물 접합체 | |
| US20250049941A1 (en) | ANTI-CD39 Antibody-Drug Conjugate And Use Thereof | |
| CN101277716A (zh) | 治疗癌症的抗体 | |
| US20250163175A1 (en) | pH-DEPENDENT ANTI-SULFATED GLYCOSAMINOGLYCAN ANTIBODY AND ANTIBODY-DRUG CONJUGATE | |
| WO2026011073A1 (en) | Antibody drug conjugates | |
| WO2026018064A1 (en) | Multispecific multi-drug antibody-drug conjugates | |
| WO2023133452A1 (en) | Methods of treating solid tumors and compositions thereof | |
| CN121130103A (zh) | 靶向cldn 18.2的抗体药物偶联物及其应用 | |
| IL318911A (en) | Humanized antibodies against NECTIN-4 and their drug conjugates |